Fourth quarter and full year results 2023
January 31, 2024 | Basel, Switzerland
Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)
Condensed financial report (PDF 0.6 MB)
Download the podcast (MP3 34 MB)
Download the presentation (PDF 5.5 MB)
Novartis Q4 2023 Impact and Sustainability Update (PDF 0.6 MB)
Investors event calendar
View recent presentations and learn more about upcoming events.
April 23, 2024
First quarter 2024 results
Basel, Switzerland
Environmental, Social and Governance (ESG)
Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.
ESG updates: February 2024 (PDF 0.6 MB) | November 2023 (PDF 1.0 MB) | August 2023 (PDF 0.3 MB) | May 2023 (PDF 1.9 MB)
Latest updates: Impact & Health Equity (PDF 9.9 MB) | Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Reporting and transparency hub
Read our regulatory filings; policies, codes and guidelines that govern our activities; and environmental, social and governance (ESG) disclosures.
Media releases
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland